Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Requirements for Human Life01:26

Requirements for Human Life

14.0K
The Earth and its atmosphere have provided humans with air, water, and food, but these are not the only requirements for survival. Humans also require a specific range of temperature and pressure that the Earth and its atmosphere provides.
Oxygen
Atmospheric air is only about 20 percent oxygen, but that oxygen is a key component of the chemical reactions that keep the body alive, including the reactions that produce ATP. Brain cells are susceptible to a lack of oxygen because they require a...
14.0K
The Angiosperm Life Cycle02:39

The Angiosperm Life Cycle

72.7K
Plants have a life cycle split between two multicellular stages: a haploid stage—with cells containing one set of chromosomes—and a diploid stage—with cells containing two sets of chromosomes. The haploid stage is the gamete-producing gametophyte, and the diploid stage is the spore-producing sporophyte.
72.7K
Characteristics of Life01:23

Characteristics of Life

262.3K
Biology is a natural science that studies life and living organisms, including their structure, function, development, interactions, evolution, distribution, and taxonomy. The field's scope is extensive and divided into several specialized disciplines, such as anatomy, physiology, ethology, genetics, and many more. All living things share a few key traits, including cellular organization, heritable genetic material and the ability to adapt/evolve, metabolism to regulate energy needs, the...
262.3K
Half-life of a Reaction02:42

Half-life of a Reaction

39.2K
The half-life of a reaction (t1/2) is the time required for one-half of a given amount of reactant to be consumed. In each succeeding half-life, half of the remaining concentration of the reactant is consumed. For example, during the decomposition of hydrogen peroxide, during the first half-life (from 0.00 hours to 6.00 hours), the concentration of H2O2 decreases from 1.000 M to 0.500 M. During the second half-life (from 6.00 hours to 12.00 hours), the concentration decreases from 0.500 M to...
39.2K
Transcytosis of IgG01:15

Transcytosis of IgG

4.2K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
4.2K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.8K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IL-2 mutein promotes antigen-specific transplant acceptance in mice through expansion of ST2<sup>+</sup> regulatory T cells.

Nature communications·2026
Same author

Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19.

The Journal of infectious diseases·2026
Same author

Selective impact on regulatory T cells with sustained functional phenotypes by the interleukin-2 mutein VIS171 in a nonhuman primate model.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19.

Infectious diseases and therapy·2026
Same author

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY).

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models.

The Journal of clinical investigation·2024
Same journal

Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic.

mAbs·2026
Same journal

Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning.

mAbs·2026
Same journal

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle<sup>TM</sup> variants.

mAbs·2026
Same journal

Development of single-chain C1q affinity chromatography-mass spectrometry for the glycoform-resolved characterization of low-affinity immunoglobulin G interactions.

mAbs·2026
Same journal

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency.

mAbs·2026
Same journal

Comparison of knockdown approaches for the generation of stable cell populations expressing afucosylated antibodies.

mAbs·2026
See all related articles

Related Experiment Video

Updated: Feb 8, 2026

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

19.3K

Extending human IgG half-life using structure-guided design.

Brian J Booth1, Boopathy Ramakrishnan1, Kristin Narayan1

  • 1a Visterra, Inc., Waltham , MA , USA.

Mabs
|June 28, 2018
PubMed
Summary
This summary is machine-generated.

Researchers engineered antibodies to extend their lifespan by improving binding to the neonatal Fc receptor (FcRn). This novel framework enhances antibody pharmacokinetics while preserving crucial effector functions.

Keywords:
AntibodyFcRnamino acid interaction networkeffector functionshalf-lifeneonatal Fc receptorpharmacokineticsstructure-guided engineering

More Related Videos

Profiling Anti-Neu5Gc IgG in Human Sera with a Sialoglycan Microarray Assay
09:13

Profiling Anti-Neu5Gc IgG in Human Sera with a Sialoglycan Microarray Assay

Published on: July 13, 2017

10.0K
A Guide to Production, Crystallization, and Structure Determination of Human IKK1/&#945;
11:27

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

9.6K

Related Experiment Videos

Last Updated: Feb 8, 2026

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

19.3K
Profiling Anti-Neu5Gc IgG in Human Sera with a Sialoglycan Microarray Assay
09:13

Profiling Anti-Neu5Gc IgG in Human Sera with a Sialoglycan Microarray Assay

Published on: July 13, 2017

10.0K
A Guide to Production, Crystallization, and Structure Determination of Human IKK1/&#945;
11:27

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

9.6K

Area of Science:

  • Biotechnology and Pharmaceutical Sciences
  • Immunology
  • Structural Biology

Background:

  • Antibody engineering aims to improve pharmacokinetics via enhanced neonatal Fc receptor (FcRn) binding.
  • Traditional methods like random mutagenesis have limitations in optimizing critical antibody attributes beyond half-life.

Purpose of the Study:

  • To develop a structure- and network-based framework for simultaneously analyzing IgG interactions with multiple Fc receptors.
  • To identify mechanisms for enhancing FcRn binding and understand allosteric effects on other Fc receptor interactions.

Main Methods:

  • Developed a computational framework integrating structural and network analyses.
  • Interrogated simultaneous engagement of IgG with FcRn, C1q, TRIM21, FcγRI, FcγRIIa/b, and FcγRIIIa.
  • Engineered Fc variants based on identified interaction features.

Main Results:

  • Identified key features governing Fc-FcRn interactions and distinct pathways for pH-specific binding enhancement.
  • Network analysis revealed allosteric impacts of FcRn-enhancing mutations on FcγR engagement.
  • Engineered Fc variants demonstrated enhanced FcRn binding, maintained biophysical stability, and wild-type-like binding to activating receptors.

Conclusions:

  • The developed framework enables simultaneous interrogation of Fc receptor interactions.
  • Engineered antibodies show significantly improved half-life in vivo (>9-fold in mice, >3.5-fold in monkeys) while retaining effector functions.
  • This approach offers a rational strategy for designing next-generation antibody therapeutics with improved pharmacokinetic profiles.